MSD DPP-4 inhibitor doesn’t increase CV risk in diabetes, heart patients

Sigma trials diabetes pilot; index finger with pinprick of blood as in diabetes testing
small drop of blood on the tip of a finger
A major study of 14,671 patients from 38 countries with type 2 diabetes and established cardiovascular disease has found that a DPP-4 inhibitor does not increase the risk for major adverse CV events, hospitalisation for heart failure or adverse events. The study was published in the NEJM this week and presented at the American Diabetes

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Guild member fees slashed by 25% for a year
Next Colorectal cancer treatment shows benefit